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Abstract
Introduction: The intra-helical cleavage of type II collagen by proteases, including collagenases and cathepsin K, is
increased with aging and osteoarthritis (OA) in cartilage as determined by immunochemical assays. The distinct
sites of collagen cleavage generated by collagenases and cathepsin K in healthy and OA human femoral condylar
cartilages were identified and compared.
Methods: Fixed frozen cartilage sections were examined immunohistochemically, using antibodies that react with
the collagenase-generated cleavage neoepitopes, C2C and C1,2C, and the primary cleavage neoepitope (C2K)
generated in type II collagen by the action of cathepsin K and possibly by other proteases, but not by any
collagenases studied to date.
Results: In most cases, the staining patterns for collagen cleavage were similar for all three epitopes: weak to
moderate mainly pericellular staining in non-OA cartilage from younger individuals and stronger, more widespread
staining in aging and OA cartilages that often extended from the superficial to the mid/deep zone of the tissue. In
very degenerate OA specimens, with significant disruption of the articular surface, staining was distributed
throughout most of the cartilage matrix.
Conclusions: Cleavage of collagen by proteases usually arises pericellularly around chondrocytes at and near the
articular surface, subsequently becoming more intense and extending progressively deeper into the cartilage with
aging and OA. The close correspondence between the distributions of these products suggests that both
collagenases and cathepsin K, and other proteases that may generate this distinct cathepsin K cleavage site, are
usually active in the same sites in the degradation of type II collagen.
Introduction
Type II collagen (Col II), the major structural compo-
nent of the articular cartilage, is composed of three
identical a chains that form collagen fibrils. The
mechanical properties and tensile strength of cartilage
depend to a large degree on the integrity of the mesh-
like endoskeleton formed by bundles of collagen fibrils
with different orientations and diameters in each of the
four zones of articular cartilage [1]. Under non-inflam-
matory conditions, collagen turnover is mediated by the
only cell type found in articular cartilage, the chondro-
cyte. Increased catabolic responses in osteoarthritis
(OA) mediated by chondrocytes involve enhanced clea-
vage of type II collagen by collagenases [2].
Until recently, collagenases were the only connective
tissue proteases known to initiate the intra-helical clea-
vage and denaturation of type II collagen but there is
emerging evidence that collagen degradation in OA
[3-6] and inflammatory arthritis [7] may also involve
action of cathepsin K, a member of the papain super-
family of cysteine proteases, which is capable of cleaving
triple helical fibrillar collagens at multiple sites, [8,9]
other than the collagenase cleavage site [4].* Correspondence: jmort@shriners.mcgill.ca1Genetics Unit, Shriners Hospitals for Children, 1529 Cedar Avenue, Montreal,
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Damage to articular cartilage results in the loss of the
tensile properties, which is determined by the collagen
fibrillar network [10]. Cartilage swelling and deforma-
tion associated with cartilage collagen degradation is
one of the hallmarks of early OA [11]. Articular chon-
drocytes express collagenases (MMP-1, 8, 13 and 14)
that belong to the matrix metalloproteinase (MMP)
family and the cysteine protease cathepsin K, both of
which are capable of cleaving the triple helical region of
type II collagen at specific and distinct sites [8,12]. Col-
lagenases are known to cleave the collagen triple helical
monomers towards the C-terminal end, resulting in the
generation of three-quarter and one-quarter length frag-
ments. Cathepsin K, on the other hand, is known to
cleave not only Col II extrahelical regions (telopeptides),
resulting in fibril depolymerization, but also the triple-
helical region, for example, at a site located 58 residues
from the N-terminus of the triple helix [8] (Figure 1).
This cleavage pattern is considered unique among other
proteases and it does not depend on previous destabili-
zation of the triple helix. Collagenases, such as MMP-
13, do not generate this cleavage [4].
Antibodies raised against the C-terminal neoepitopes
generated in the triple-helical region of the collagen
fibril by cathepsin K and by collagenases were used in
the development of immunochemical assays that quanti-
tate cleavage at these sites. The levels of both of these
neoepitopes in extracts of human articular cartilage
were shown to be significantly increased in aging and an
even greater increase was seen in OA. Moreover, gen-
eration of the cathepsin K neoepitope in OA cartilage
was arrested in culture by a specific cathepsin K inhibi-
tor [4]. Together these observations suggest that cathe-
psin K is involved in the generation of this neoepitope
and that it can be involved in collagen cleavage in OA
cartilage.
The purpose of the present study was to identify and
compare, using immunohistochemistry and specific anti-
neoepitope antibodies, the locations of these two distinct
intrahelical cleavage sites in Col II that are generated
either by collagenases or by cathepsin K in both healthy
aging and OA cartilages.
Materials and methods
Tissue
Human femoral condylar cartilages that appeared
macroscopically normal were obtained at autopsy from
12 individuals of both sexes in the age range of 19 to 69
years. Full depth cartilage (0.5 to 1.0 cm2 surface area)
was removed with a scalpel within 15 h of death. OA
cartilage was obtained at total knee arthroplasty [2]
from seven patients (55 to 75 years) with OA diagnosed
in accordance with the criteria of the American College
of Rheumatology [13]. Samples were stored at -20°C
prior to use. Ethical approval from the McGill Univer-
sity Institutional Research Board was granted for these
studies and informed consent was obtained from the
patients or next of kin for all samples used.
Antibodies
The antibodies that were used to assess the degradation
of type II collagen by collagenases have been described
previously (Figure 1). They include a mouse monoclonal
antibody against the collagenase-generated primary clea-
vage neoepitope (C2C, previously termed COL2 3/4C
(long)) [14] and rabbit polyclonal antibodies against the
primary collagenase-generated C1,2C epitope (previously








Figure 1 Peptide sequences used for the preparation of collagen cleavage antibodies. The cleavage positions of cathepsin K and
collagenase in the triple helical domain of type II collagen are indicated. Small grey arrows designate the minor collagenase cleavage positions
recognized by the C1,2C antibody following reaction at the primary site. The sequences of the collagen molecule forming the C-terminus of the
fragments generated on cleavage represent the C2K, C2C and C1,2C epitopes. P* denotes 4-hydroxyproline.
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potential to recognize this neoepitope present at three
other sites in the a chains of type II collagen once the
triple helix has been cleaved. A rabbit polyclonal anti-
serum raised against the C-terminal neoepitope (C2K)
of the short a chain fragment generated by cathepsin K
(but not by collagenases) in type II collagen [4] was
used to identify the location of this cleavage site. A
BLAST search has revealed that this antiserum could
also recognize the same neoepitope sequence in the type
I collagen a1 chain although there is no direct evidence
for cathepsin K cleavage of type 1 collagen at this site.
While type II is the predominant collagen in articular
cartilage, the presence of minor amounts of type I has
been reported based on immunohistochemical studies
[15]. However, no evidence for the mRNA for type I
chains was found in osteoarthritic cartilage [16].
Immunohistochemistry
The methods used for immunolocalization of extracellu-
lar matrix in articular cartilages were similar to those
described previously [17,18]. Briefly, the tissue samples
were thawed, mounted and refrozen in OCT embedding
media, then cryosectioned (6 μm thick sections) using a
Tissue-Tek II cryostat. Sections were either refrozen and
stored at -20°C or used immediately. The variable nature
of the clinical material available limited our ability to
obtain serial sections. For comparative purposes, an
effort was made to use sections from as close as possible
within the tissue sample, ideally two or three sections.
Fixation of the sections and subsequent procedures were
performed at room temperature. Samples were fixed for
5 minutes in 4% formaldehyde prepared fresh from par-
aformaldehyde hydrolyzed in PBS, followed by 3 × 10-
minute washes in PBS. The permeability of the cartilage
matrix was enhanced by treating with chondroitinase
ABC (ICN/Flow Laboratories, Mississauga, ON, Canada)
at 0.0125 U/50 μl per section in 0.1 M Tris-acetate buf-
fer, pH 7.6, for 90 minutes at 37°C to remove glycosami-
noglycans. This was followed by 1 h incubation in 0.2 M
EDTA in 50 mM Tris, pH 7.6 for removal of calcified
deposits, which would otherwise non-specifically bind
immunoglobulins. Endogenous peroxidase activity was
blocked by incubation of the sections with freshly pre-
pared 0.5% v/v H2O2 in absolute methanol for 10 min-
utes followed by washing in PBS for 15 minutes.
Unreactive aldehyde groups were blocked with 5% nor-
mal pig serum in PBS for 30 minutes. For the detection
of the cathepsin K-induced neoepitope, the sections
were incubated for 30 minutes at room temperature
with 50 μl/section of rabbit antiserum R771 diluted
1:200 in PBS, 1% w/v BSA [4]. Two types of controls
were prepared, one by using non-immune rabbit serum
and the other by preincubating the polyclonal antiserum
with the 100 μg/ml of the immunizing peptide, as
described [17]. The secondary antibody consisted of bio-
tinylated pig anti-rabbit F(ab’) (Dako Cedarlane, Hornby,
ON, Canada), diluted 1:800 in PBS, 1% w/v BSA. After
30 minutes incubation with the secondary antibody, the
sections were washed 3 × 10 minutes in PBS and further
incubated for 20 minutes with the indicator, a streptavi-
din-horseradish peroxidase conjugate (Amersham Bios-
ciences, Baie d’Urfe, QC, Canada), diluted 1:300.
The same technique was used for the detection of col-
lagenase-induced cleavage of Col II by using diluted rab-
bit antiserum (1:200) raised against the C1,2C
neoepitope and diluted mouse ascitic fluid (1:200) raised
against the C2C neoepitope. The secondary antibody for
the C2C neoepitope was biotinylated rabbit anti-mouse
F(ab’), diluted 1:600. The peroxidase reaction was per-
formed with copper-H2O2/silver intensification of the
nickel-diaminobenzidine end-product of the peroxidase
reaction as previously described [19]. After washing, the
tissue sections were mounted with VectaMount mount-
ing medium (Vector Laboratories, Burlington, ON,
Canada) and examined with light microscopy.
Results
Full-depth articular cartilage sections were examined
from 12 non-arthritic individuals of age 19 to 69 years
and from 7 OA patients of age 55 to 75 years. Collage-
nase generated cleavage products were detected using
the polyclonal antibody to the C1,2C epitope (Figure 1),
which is specific for the C-terminus of the initial proteo-
lytic product and a monoclonal antibody to the C2C
epitope. We used both reagents since they recognize
neoepitopes of varying length and their combined use
has never been reported previously. The monoclonal
antibody is specific for type II collagen since it only
recognizes the C2C neoepitope that resides at the C-
terminus of the TCA fragment produced by cleavage of
type II collagen a1 monomer by collagenases [14];
whereas, the polyclonal antibody recognizes the shorter
neoepitope, which results from secondary cleavage gen-
erating the C1,2C epitope and is found in both type II
and type I collagen [2]. The cathepsin K derived Col II
neoepitope was localized using the C2K antibody.
We describe below the extracellular staining which is
of particular interest and was found to be specific, based
on control studies involving immunogen preabsorption
of the polyclonal and monoclonal antibodies. In all
cases, very weak extracellular staining was observed
when the sections were treated with non-immune rabbit
sera or with antisera/ascitic fluid preincubated with the
peptides against which the antibodies were raised. For
example, treatment of OA cartilage with pre-absorbed
antibodies (Figure 2), resulted in very weak and diffuse
staining compared to the very intense staining obtained
when cartilage sections were incubated with the
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unabsorbed antibodies, demonstrating the specificity of
extracellular staining.
Weak to moderate extracellular staining was usually
observed in similar sites with all three antibodies around
chondrocytes (5/6 cases) in each of the non-arthritic tis-
sues obtained from younger individuals (under 50
years). Staining was seen throughout the full depth of
the articular cartilage (Figure 3A, D) or mainly close to
the articular surface (Figure 3C, E, F), which was essen-
tially intact. With increasing age (over 49 years), usually
more intense pericellular and diffuse extracellular stain-
ing was observed, extending from the articular surface
into the mid (Figure 4D) and deep zones (Figure 4B). It
was more pronounced in pericellular sites but some-
times extended to territorial and interterritorial sites.
The extracellular staining pattern was in general very
similar for each of the three antibodies but in most
cases a stronger or more diffuse staining was observed
for the sections treated with C1,2C antibody compared
to C2C, which may result from the recognition of sec-
ondary cleavage sites in Col II. Only in one case was
cleavage of Col II by cathepsin K different from that
detected for collagenases (Figure 4A). Here cleavage of
Col II by collagenases was present in the territorial
matrix around chondrocytes of all cartilage zones,
whereas cleavage by cathepsin K was only located in the
mid and deep zones. In this case the cartilage samples
varied somewhat between sections due to the difficulty
in obtaining acceptable sections. One example (Figure
3B) showed strong pericellular staining for cleavage by
collagenases in the superficial and mid zones, as
opposed to a thin band of diffuse staining confined to
the superficial zone indicating cleavage by cathepsin K.
OA cartilages exhibited more abundant and wide-
spread intense extracellular staining compared to the
non-arthritic group. The staining patterns were different
from one case to another but, again, usually similar for
all antibodies and in some instances the distribution of
staining was similar to, but more pronounced than, that
observed in nonarthritic cartilages from older subjects
(Figure 5D, F). Pericellular staining extended from the
articular surface into the mid and deep zones (Figure
5B, C, E) and extensive diffuse staining present in peri-
cellular, territorial and interterritorial sites was some-
times pronounced in the superficial, mid and upper
deep zones (Figure 5A, F).
In other cases (Figure 5B, C), a reduction or loss of
staining was observed under the articular surface
accompanied by stronger pericellular, territorial and
interterritorial staining in the mid and deep zones.
Figure 2 Demonstration of antibody specificity. High magnification views of articular cartilage from a 69-year-old OA patient, showing
cleavage of type II collagen by collagenases (C1,2C and C2C) and cathepsin K (C2K). Control (A) was prepared by prior absorption of the
antisera with the immunizing peptides. Immune staining (B) using unabsorbed antibodies. Bar = 200 μm.
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Stronger, diffuse staining throughout most of cartilage
thickness was observed in both fibrillated cartilages (Fig-
ure 5C, E) and in cartilages with intact articular surface
(Figure 5A). Figure 5A shows a very clear delimitation
between the strong, diffuse and extensive matrix staining
in the zone of enhanced collagen cleavage compared to
staining deeper in the cartilage where it is only
pericellular.
Discussion
Osteoarthritis with its accompanying cartilage degenera-
tion is a common consequence of aging [20]. Many
components of the tissue matrix undergo aging changes,
including the major proteoglycan, aggrecan [21], the
various collagenous components [22] and the chondro-
cytes themselves [23]. Excessive proteolysis has long
been recognized as a major contributory factor to carti-
lage matrix degradation in OA. A variety of proteases
have been implicated, ranging from lysosomal cysteine
proteases, such as cathepsin B, which can cleave aggre-
can and non-helical telopeptide sites in Col II, to
MMPs, such as MMP-3 (stromelysin), aggrecanases and
collagenases [24]. Collagen degradation is considered to
be a key process in articular cartilage degeneration in
OA [2]. Collagenases are involved in normal extracellu-
lar turnover of collagen but their up-regulation is asso-
ciated with the generation of inflammatory mediators
[25], which are believed to play a central role in the
pathology of OA [26]. Enhanced Col II degradation by
collagenases has been detected in OA articular cartilages
[2,27] together with increased denaturation of Col II
that results from intrahelical cleavage of Col II [17,18].
It has long been considered that MMPs with the capa-
city to generate the classic collagenase cleavage site are
the principal proteases capable of cleaving triple helical
collagen. Recent studies have provided evidence that
collagen degradation in health and disease may also
involve the action of cathepsin K [4,5,7], a cysteine pro-
tease that is up-regulated in OA chondrocytes [3] and is
capable of degrading native triple helical collagens,
including Col II [4,8], as well as other matrix molecules
of the hyaline cartilage, such as aggrecan [28].
The ability of cathepsin K to cleave native Col II at
sites in the triple helix distinct from that of the pri-
mary collagenase cleavage site [4,8], renders it unique
among other tissue proteases. The present study,
which used immunoperoxidase localization to identify
and compare the distribution of Col II cleavage neoe-
pitopes generated by these different proteases in
healthy and OA cartilages, was prefaced by analytical
immunoassays of these articular cartilages with the
antibodies C2C and C2K, which revealed a significant
increase in the generation of these two neoepitopes in
aging and more so in OA cartilage [4]. Using immuno-
localization in the present study, we were able to
demonstrate the more widespread distribution of Col
II cleavage in arthritic cartilage and to identify the
sites of more intense proteolytic activity within the
Figure 3 Immunostaining of cartilage from young normal
individuals. Sections of human femoral condylar cartilage from six
non-OA individuals (ages 19 to 47 years), showing detection of
neoepitopes generated by collagenases (C1,2C and C2C) and
cathepsin K (C2K) in type II collagen. Specimens are positioned so
that the articular surface is at the top of each figure. Bar = 200 μm.
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Figure 4 Immunostaining of cartilage from older normal individuals. (A-E) Sections of human femoral condylar cartilage from five non-OA
individuals (ages 50 to 68 years), showing detection of neoepitopes generated by collagenases (C1,2C and C2C) and cathepsin K (C2K) in type II
collagen. High-magnification views (C and D) were used to better indicate pericellular staining. Bars = 200 μm.
Dejica et al. Arthritis Research & Therapy 2012, 14:R113
http://arthritis-research.com/content/14/3/R113
Page 6 of 9
tissue. Moreover, we showed that sites of cleavage of
Col II by collagenases are usually co-localized with
sites where the cathepsin K cleavage neoepitope is also
found, suggesting that different proteases are active in
sites of Col II cleavage in both normal and arthritic
cartilages.
Our results for the collagenase neoepitope analyses
complement our earlier data [18] and demonstrate that
in the majority of cases similar results were obtained
with both C1,2C and C2C antibodies. In the cases
where differences were observed with more staining for
C1,2C, this may result from secondary cleavages in the
collagen a chain (Figure 1), which would only be recog-
nized by the C1,2C antibody. Our results further indi-
cate that Col II degradation usually starts around
chondrocytes, in the upper region of cartilage, at and
close to the articular surface, with progressive involve-
ment of the mid and deep zones in aging and OA. A
“stepwise” activation of chondrocytes by cytokines
initiated in the superficial cartilage, slowly extending
through chondrocyte activation into the deeper zones
may account for the clear demarcation between the
severely degenerate extracellular matrix and the more
normal underlying cartilage. This “creeping substitution”
of good with bad appears to be the manner whereby
cartilage damage extends ever deeper into the cartilage
with time. However, which cytokines stimulate cathepsin
K expression in chondrocytes remains to be determined.
In most specimens that were used for the study, a
similar distribution was observed for both collagenase
and cathepsin K-generated cleavage of Col II. The sites
of collagen degradation by collagenases are known to
correlate with the distribution of the collagenases
MMP-1 and MMP-13 in both healthy and OA cartilages
[18]. On the other hand, cathepsin K positive cells have
been identified in all zones of degraded cartilage and
there is evidence that cathepsin K may be released into
the extracellular matrix, as indicated by immunohisto-
chemical detections of the enzyme in the territorial
matrix around cells [3]. Recently, in a study of equine
OA, use of the same antiserum to the neoepitope gener-
ated by cathepsin K revealed that sites of extracellular
collagen cleavage were increased in degenerate cartilage
and co-localized with cathepsin K staining [29]. These
and our present and recent findings [4] together indicate
that cleavage of Col II as detected in this study can
involve both collagenases and cathepsin K that originate
from chondrocytes.
Concomitant with aging in human cartilage, the accu-
mulation of advanced glycation end products has been
shown to decrease the susceptibility of this tissue to
proteolytic degradation [30,31]. Our immunohistochem-
ical findings are consistent with this progressive cross-
linking of the cartilage matrix, which limits the ability of
cleavage products to be released from the tissue. This
appears to account for the increased staining intensity
of the collagen neoepitopes with age and the require-
ment for extensive chymotrypsin pretreatment of the
Figure 5 Immunostaining of cartilage from osteoarthritic
patients. Sections of human femoral condylar cartilage from six OA
patients (ages 55 to 70 years), showing detection of neoepitopes
generated by collagenases (C1,2C and C2C) and cathepsin K (C2K)
in type II collagen. Bar = 200 μm.
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tissue for immunoassay quantitation. In addition, despite
a major effort, we have been unable to biochemically
characterize the collagen peptides bearing the cathepsin
K neoepitope. The product of in vitro collagen cleavage
was detectable by immunoassay but was not demon-
strable by Western blotting even when high percentage
polyacrylamide gels were used.
The present study mainly provides information
regarding the distribution of collagen degradation
within the tissue. Making quantitative estimates to
compare the amount of epitopes generated by each of
the enzymes is not possible since the antibody dilu-
tions were adjusted to give the strongest specific anti-
gen staining with the lowest non-specific background.
However, our recent quantitative analyses also revealed
a significant correlation between cleavage generated by
collagenases and that which can be generated by cathe-
psin K [4]. The present study indicates that Col II
cleaving activity of the kind generated by cathepsin K
is usually evident in the same sites as collagenase
activity in both normal and diseased cartilages. Both
studies thus revealed that neoepitopes are generated by
both collagenases and cathepsin K in the same sites
and increase with age and more so with OA and that
these events are correlated in some way. That this
non-collagenase cleavage is produced by cathepsin K is
supported by our recent observation that the genera-
tion of the cathepsin K neoepitope in OA cartilage
from some patients in culture can be inhibited by a
specific non-toxic inactivator of this cysteine protease
[4]. In patients where inhibition was not observed, it
appears that cathepsin K was not active in that period
of time. This does not preclude the enzyme from being
active at other times in these patients. But it also raises
the issue of whether proteases other than cathepsin K
and collagenases, the latter having not been shown by
us to generate this cathepsin K cleavage neoepitope,
may also produce this neoepitope. In fact, there have
been several studies which have identified other clea-
vage sites in Col II distinct from those described here
with no evidence for a single protease being involved
in their generation [32-34]. In a recent proteomic
study [35], products of human articular cartilage
digested in vitro with a series of MMPs and aggreca-
nases were characterized. While a large number of Col
II cleavage products were identified, none were compa-
tible with cathepsin K activity. Thus, only the collage-
nase generated neoepitope would appear to be specific
for this protease [2,14].
Together these results suggest that whereas collage-
nases may be the dominant mediator of Col II, cleavage
in a majority of patients, cathepsin K and other pro-
teases may also play a significant role. In both normal
aging and in cartilage degeneration accompanying
osteoarthritis, the degradative processes mediating col-
lagen cleavage by these enzymes appear to be similar.
Conclusions
Collagen degradation is a hallmark of cartilage destruc-
tion in osteoarthritis. In addition to the well-accepted
role of matrix metalloproteinase collagenases in this
process, immunohistochemical staining of cartilage from
osteoarthritis patients, together with previous immu-
noassay data demonstrates the role for cathepsin K in
this process. The similarity in distribution of the clea-
vage products attributed to the two different enzyme
types suggests their production by the same cells at and
close to the articular surface and that the destruction of
collagen is mediated by similar mechanisms during nor-
mal aging and osteoarthritis.
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